New medical AI launches, from India to Korea
New medical AI launches, from India to Korea unknown
Indian medical imaging AI company InMed AI has released a new AI-powered tool for screening traumatic brain injuries (TBI).
The Neuroshield CT TBI is a decision support tool for detecting and quantifying intracranial haemorrhage, fracture, and midline shift. Utilising AI, it automatically processes brain CT images and alerts clinicians of critical findings.
Commenting on the technology, Dr Deepak Agrawal, professor of Neurosurgery at All India Institute Of Medical Science Trauma Centre in New Delhi, said: "Using this solution, patients can be automatically triaged for review by a neurosurgeon, and patients with normal scans can be discharged without [the] intervention of radiologists or neurosurgeons."
This launch follows the United States Food and Drug Administration 510(k) clearance that In-Med received for its volumetric brain analysis software NeuroShield.
Qure.ai has announced that its AI-enabled tuberculosis solution has been given a breakthrough device designation by the US FDA. The qSpot-TB analyses chest X-rays to locate findings indicative of TB.
Just last month, the company received the US FDA's approval for qXR for Lung Nodule, which is said to be the first approved solution for lung nodules screening.
VUNO will supply its AI-based chest X-ray solution to South Korean medical diagnostic X-ray systems brand DRGem.
It recently signed a deal to integrate the VunoMed Chest X-ray into DRGem's line of X-ray devices. This comes after DRGem has verified the technology with hospitals overseas. The X-ray equipment supplier sells its products locally and across North America, Europe, and the Middle East.
Another South Korean company, Kakao Brain, has unveiled its latest web-based solution that incorporates AI for supporting chest disease diagnoses.
Featuring KARA-CXR (Kakao Brain AI for Radiology Assistant CXR), the radiology support solution provides both simple and detailed AI-driven reports, which can also be shared with outside organisations. It also enables the uploading of multiple DICOM files and receiving multiple reports.
The research-use-only solution, built on Kakao Brain's own generative AI, also anonymises personal information in DICOM files to protect data privacy.
The company has been developing KARA-CXR since 2022, in collaboration with 11 university hospitals and big medical institutions across South Korea. It has analysed over 16 million chest X-ray images and analyses to date.
Kakao Brain is now working to get regulatory approvals for its solution in South Korea, the United States, and Europe. CEO Kim Il-doo also disclosed that they are planning to expand their AI solutions to include "interactive functions that support a variety of medical imaging tests."